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1  | INTRODUC TION
Haemophilic arthropathy is the result of repetitive intra‐articular 
bleeding and synovial inflammation.1 In the lower limb, haemophilic 
arthropathy commonly affects the range of motion of the knee and 
ankle joints and has also an impact on muscle size, muscle force 
capacity and proprioception.1,2 While the interest in the musculo‐
skeletal properties and biomechanics of movement of people with 
haemophilic arthropathy (PWHA) has recently increased,3,5‐7 the ef‐
fects of haemophilic arthropathy on neuromuscular control during 
gait have not been investigated.
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Introduction: Effects of haemophilic arthropathy on neuromuscular control during 
gait are currently unknown.
Aims: (a) To assess how haemophilic arthropathy affects the complexity of neuro‐
muscular control during gait; (b) To investigate the relationship between complexity 
of neuromuscular control and joint impairment.
Methods: Thirteen control subjects (CG) walked overground at their preferred and a 
slow velocity and thirteen people with haemophilic arthropathy (PWHA) walking at 
their preferred velocity. Surface electromyography (EMG) was collected from eleven 
leg muscles. Electromyography variance explained by muscle synergies (sets of co‐
activated muscles that can be recruited by a single signal) was calculated by the total 
variance accounted (tVAF). Three measures were used to evaluate complexity of neu‐
romuscular control: (a) the number of synergies required for tVAF > 90%, (b) tVAF as 
a function of the number of muscle synergies, and (c) the dynamic motor control 
index (Walk‐DMC). Impairment of ankle and knee joints was determined by the 
Haemophilia	Joint	Health	Score	(HJHS).
Results: The same number of the muscle synergies was found for each group 
(P > 0.05). For both walking velocities tested, tVAF1 was higher in PHWA (P < 0.05). 
The Walk‐DMC of PWHA was lower than that of the CG for both walking velocities 
(P	<	0.05).	For	PWHA,	no	significant	correlation	was	found	between	HJHS	(sum	knee	
and ankle) and Walk‐DMC index (r	=	−0.32,	P = 0.28).
Conclusions: These results indicate differences between PWHA and CG in the neu‐
romuscular control of gait. The Walk‐DMC and tVAF1 may be useful measures to 
assess changes in neuromuscular control in response to treatment.
K E Y W O R D S
ankle joint, haemophilia, knee joint, muscle synergy, neuromuscular control, surface 
electromyography
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Instead of focusing on the activity patterns of individual muscles, 
the neuromuscular control of motor tasks can be described by mus‐
cle synergies,8‐10 A muscle synergy is a group of muscles that are re‐
cruited simultaneously (ie co‐activated) with distinct relative levels 
of activation. The central nervous system (CNS) is presumed to pro‐
duce movements not by activating individual muscles, but by acti‐
vating muscle synergies.8‐10 In healthy individuals, it has been shown 
that a large part (>90%) of the variance in muscle activity during gait 
can be described by a limited number (4‐5) of muscle synergies.11,12
The same approach has been applied in several neurological 
diseases (ie cerebral palsy, Parkinson, stroke and incomplete spinal 
cord injury). Patients were found to use a lower number of muscle 
synergies and altered structure of the synergies, which was related 
to functional and clinical assessments.13‐16 A lower number of syn‐
ergies is interpreted as a more simplified (ie decreased complexity) 
control by the CNS. When applied in musculoskeletal diseases (ie 
sacroiliac joint pain, anterior cruciate ligament‐deficient, gluteal ten‐
dinopathy), also a different synergy structure compared to a con‐
trol group was observed, but no difference in the number of muscle 
synergies.17‐19
Recently, a new measure has been proposed called the Walking 
Dynamic Motor Control Index (Walk‐DMC), which is based on the 
total EMG variance explained by one synergy.15 The Walk‐DMC 
has been proposed as a potential metric to assess the complexity 
of motor control and was shown to be associated with clinical out‐
comes after conservative treatment and orthopaedic surgery in pa‐
tients with cerebral palsy.15,20,21 Applying measures of complexity of 
neuromuscular control may also be a valuable clinical tool to assess 
the level of neuromuscular impairment in PWHA with different lev‐
els of joint damage.
The aims of this study are as follows: (a) to assess how haemo‐
philic arthropathy affects the complexity of neuromuscular control 
during gait, (b) to investigate the relationship between complexity of 
neuromuscular control and joint impairment.
2  | MATERIAL AND METHODS
2.1 | Participants
This study was approved by the local ethical committee and con‐
ducted in agreement with the Declaration of Helsinki. All par‐
ticipants were informed about the purpose and procedures of the 
project and gave their written informed consent to participate in 
the study. Based on non‐probability sampling, thirteen PWHA were 
recruited in two hospitals in Santiago (Chile), and thirteen healthy 
control subjects (student and employees) were recruited from the 
University of Chile (for their characteristics see Table 1).
Inclusion criteria for PWHA: Males, diagnosed with haemophilia A 
or B, severe or moderate (severe <1% and moderate 1%‐5% of normal 
factor activity in blood), haemophilic arthropathy with a minimum of 
two points (sum knee and ankle in evaluated limb) of the Hemophilia 
Joint	Health	Score	(HJHS),	over	18	years	of	age	and	under	45	years,	
prophylaxis treatment with deficient factor (ie XIII or IX), and body 
mass index lower than 30. Exclusion criteria: History of hip, knee or 
ankle arthroplasty in the evaluated limb, equinus foot, incapacity to 
walking independently, history of muscle or joint bleeding in lower 
limbs in the last 2 months, chronic cardiac and/or respiratory pathol‐
ogy and neurological disease.
Inclusion criteria for control subject: Males over 18 years of age 
and under 45 years, no haemophilia and body mass index lower than 
TA B L E  1   Basic characteristics of the two groups
Variables CG (n = 13) PWHA (n = 13) P‐value
Age (years) 28.4 ± 6.2 28.7 ± 6.9 0.906
Body mass (kg) 75.5 ± 8.1 74.4 ± 8.7 0.280
Height (cm) 180 ± 0.04 170 ± 0.10 0.502
Body mass 
index



























NA 7.1 ± 3.3 NA
HJHS	knee	
(points)









NA 5.2 ± 4.8 NA
HJHS	knee	
(points)





NA 9.1 ± 8.9 NA
Parametric distribution: Mean ± SD. Nonparametric distribution: Median 
[Range].	CG,	control	group;	HJHS,	Hemophilia	Joint	Health	Score;	NA,	
Not applicable; PWHA, people with haemophilia; VAS, Visual Analogue 
Scale.
*P‐value <0.05. 
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30. Exclusion criteria: Scoliosis, history of acute or chronic musculo‐




In the control group (CG), the dominant limb was assessed, which 
was determined by asking the subjects which leg they would use to 
kick a ball.22
After shaving and cleaning the skin with alcohol, surface elec‐
trodes (Ag–AgCl, Kendall H124SG) were placed (interelectrode 
spacing 2 cm) on the following muscles according to SENIAM guide‐
lines23: Medial Gastrocnemius (MG), Lateral Gastrocnemius (LG), 
Soleus (SOL), Tibialis Anterior (TA), Vastus Lateralis (VL), Medialis 
(VM), Rectus Femoris (RF), Semitendinosus (ST), Biceps Femoris 
(BF), Gluteus Maximus (GMAX) and Gluteus Medius (GMED).
Muscle activity patterns were assessed using a wireless EMG 
system (MyoSystem DTS; Noraxon USA Inc, Scottsdale, CA, USA), 
with a sampling rate of 1500 Hz. Gait cycle events were detected 
by a synchronized wireless pressure sensor placed underneath the 
heel of the foot.
2.3 | Experimental protocol
To assess if subjects had a sedentary lifestyle (<150 minutes per 
week of moderate physical activity), they were asked to indicate how 
many minutes per week they were involved in physical activity.24
Each subject was invited to walk barefoot overground at their 
preferred velocity and the CG also walked at a slower velocity sim‐
ilar to that of the mean preferred velocity in PWHA (1.0 m/s). Each 

























The total variance accounted for (tVAF). tVAF by one synergy (tVAF1). 
Original EMG data (EMGo). Reconstructed EMG data (EMGr). Dynamic 
motor control index (Walk‐DMC). Average (AVGc) and standard devia‐
tion (SDc) of tVAF1 from the control group.
F I G U R E  1   EMG activity patterns of multiple muscles during gait. A, Example of one healthy individual (black). EMG activity patterns 
during	gait	of	two	people	with	haemophilic	arthropathy	(PWHA)	(red).	B,	Example	of	PWHA	with	low	HJHS	score	in	both	knee	and	ankle	
(knee	=	0	points;	ankle	=	2	points).	C,	Example	of	PWHA	with	high	HJHS	score	in	both	knee	and	ankle	(knee	=	8	points;	ankle	=	8	points).	The	
data show 20 gait cycles during slow velocity walking for the healthy subject (1.2 m/s) and the preferred velocity of the haemophilic patients 
(1.24 m/s and 1.03 m/s, respectively). Note that in PWHA, the EMG activity patterns of several muscles are similar indicating a high degree 
of	co‐activation	between	flexion	and	extension	muscles.	In	the	PWHA	with	high	HJHS	score	(C),	more	than	80%	of	variance	of	all	muscles	
can be explained by one synergy, while in the healthy subject one synergy explains only 54% of the variance. This can be explained by more 
co‐activation between flexion and extension muscles and has been interpreted as an indication of more simplified control by the central 
nervous system. a.u., Arbitrary unit; BF, Biceps Femoris; GMAX, Gluteus Maximus; GMED, Gluteus Medius; LG, Lateral Gastrocnemius, 
MG, Medial Gastrocnemius; RF, Rectus Femoris; TA, Tibialis Anterior; SOL, Soleus; ST, Semitendinosus; VL, Vastus Lateralis; VM, Medialis. 
The total variance accounted for one synergy (tVAF1). The dynamic motor control index (Walk‐DMC) [Colour figure can be viewed at 
wileyonlinelibrary.com]
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velocity was practiced three times for 10 m. Mean velocity was as‐
sessed by dividing total distance by total time. Subsequently, each 
subject walked barefoot for 30‐m, two times in each velocity, with 
2 minutes of rest in between tests. Between 1 and 2 hours prior to 
the experiment, patients received prophylactic treatment.
2.4 | EMG data analysis
For the EMG and synergies analysis, Matlab software was used 
(MathWorks, Inc, Natick, MA, USA). For each condition in each 
group, 20 gait cycles were included for the analysis.
A bandpass filter (20‐500 Hz) followed by rectification using 
Hilbert transformation was applied. Subsequently, EMG signals were 
low‐pass filtered at 10 Hz and per condition normalized to the maxi‐
mum value of all included cycles.25,26 Then, EMG data was time nor‐
malized to 200 points.25 Non‐negative matrix factorization (NNMF) 
was used to extract muscle synergies from the EMG signals (for a 
comprehensive description see27). Briefly, the EMGs were combined 
into an m × t matrix, where m represents the number of muscles 
(11 in this study) and cycles (20 cycles), and t is the time base (200 
points). The NMMF results in the muscle weightings (ie contribution) 
for each synergy (W) and the matrix encoding the activation pattern 
of each synergy (C). Note that the product of W and C should ap‐
proximate the original EMG data.
The NNMF algorithm was iterated 20 times for each number 
of synergies between 1 and 4, and the iteration with the lowest 
reconstruction error was selected. The difference between recon‐
struction of EMG data and the original EMG data was calculated 
using the total variance accounted for (tVAF) (Table 2, Equation 
1).13 The tVAF was calculated for an increasing number of syn‐
ergies (from 1 to 4). The number of synergies was increased until 
tVAF was >90% or until adding another synergy did increase tVAF 
by <5%.13
We used three measures to evaluate complexity of neuromuscu‐
lar control:15,28 (a) the number of synergies required for tVAF > 90%, 
(b) tVAF as a function of the number of muscle synergies and (c) 
Walk‐DMC index. The Walk‐DMC is a z‐score based upon tVAF1, 
using the average and standard deviation of tVAF1 from the healthy 
CG (Table 2, Equation 2).15 A higher tVAF1 results in a lower Walk‐
DMC score (see Figure 1).
2.5 | Clinical assessments for PWHA
To assess the intensity of pain (scale 0‐10 points) during walking 
barefoot,	the	Visual	Analogue	Scale	(VAS)	was	applied.	The	HJHS	2.1	
score is used to assess joint health status in both knees and ankles.29
2.6 | Statistical analysis
For all statistical analysis, Matlab software was used (MathWorks, 
Inc). The alpha‐level was set at 0.05. The normality of data were 
evaluated through the Shapiro‐Wilk test. Data are expressed as the 
mean ± SD.
Two assessments were made for all variables: (a) the comparison 
of CG during preferred walking velocity (CG‐pref) with PWHA, (b) 
and a comparison of CG during slow velocity (CG‐slow) with PWHA.
The Chi‐square test was used to compare the number of mus‐
cle synergies for tVAF > 90% between groups. To evaluate differ‐
ences in the tVAF as a function of number of synergies, two‐way 
repeated measures ANOVA (number of synergies × group) was 
used. Greenhouse‐Geisser correction was used if the assumption 
of sphericity, as checked by Mauchly's test, was violated. If a sig‐
nificant interaction was found between factors, post hoc tests 
with Bonferroni correction were applied. To compare the Walk‐
DMC and muscle contributions of each synergy between groups, 
the independent samples t test was used. To determine the ef‐







	≥	0.14)	 and	 Cohen's	 (d	≥	0.2,	
d	≥	0.5,	 d	≥	0.8)	 were	 calculated,	 to	 indicate	 small,	 moderate	 or	
large effects, respectively.
Finally, to assess the relationship between complexity of neu‐
romuscular	 control	 and	 joint	 impairment	 the	HJHS	 score	was	 cor‐
related with the Walk‐DMC index using Pearson correlation. In 
addition, k‐means clustering analysis was applied to identify sub‐
groups within the PWHA (ie different level of joint damage in the 
knee and/or ankle). The groups were considered distinct if the ma‐
jority of silhouette values are larger than 0.6.30 Subsequently, the 
Walk‐DMC was compared between the identified subgroups of 
PWHA with the CG‐slow using one‐way ANOVA and post hoc with 
Bonferroni correction.
3  | RESULTS
3.1 | Anthropometric and clinical characteristics
Table 1 describes participant demographic and clinical characteris‐
tics. No difference was found (P = 0.541) in walking velocity of the 
slow condition in CG and preferred velocity in PWHA (1.0 ± 0.2 and 
1.0 ± 0.2, respectively).
3.2 | Neuromuscular control
The number of muscle synergies for tVAF > 90% was not different 
between groups (ie median of four synergies, range 3‐4 for CG‐pref, 
3‐5 for CG‐slow and 3‐5 for PWHA), both when compared at pre‐
ferred walking velocity (P = 0.698) and when compared at similar 
velocity (P = 0.540).
Comparing groups at their preferred velocity (Figure 2), two‐
way repeated measures ANOVA indicated a significant differ‐
ence between groups (P = 0.020, 2
p
 = 0.21) and synergy number 
(P < 0.001, 2
p




 = 0.26). Post hoc analysis showed a significant difference 
between groups only when including one synergy (P = 0.003, 
d = 1.32). When comparing groups for the similar walking velocity 
(Figure 2), two‐way repeated measures ANOVA showed no sig‐
nificant difference between groups in tVAF as a function of the 
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number of synergies (P = 0.461, 2
p
 = 0.02). A significant differ‐
ence between synergy number (P < 0.001, 2
p
 = 0.95), and a signif‐
icant interaction between group and synergy number was found 
(P = 0.007, 2
p
 = 0.22). Post hoc analysis showed a significant differ‐
ence between groups only when including one synergy (P = 0.027, 
d = 0.93). These results indicate that in PWHA one muscle synergy 
can explain a greater part of the variance of the EMG data com‐
pared to the CG, independent of walking velocity.
For the Walk‐DMC index, the PWHA showed a lower value 
compared with CG‐preferred (P = 0.003, d = 1.32) and CG‐slow 
(P = 0.027, d = 0.92) (Figure 3). For PWHA, no significant correla‐
tion	was	found	between	HJHS	(sum	knee	and	ankle)	and	Walk‐DMC	
index (r	=	−0.32,	P = 0.28).
Regarding muscle contributions of each synergy during gait at 
the same velocity (ie 1 m/s), a higher contribution was found for BF 
(P = 0.008, d = 1.03) and a lower for RF (P = 0.023, d = 1.21) in the 
acceptance synergy of PWHA (Figure 4). During the push‐off syn‐
ergy, a higher contribution of VL (P = 0.040, d = 0.90), RF (P = 0.012, 
d = 1.10) and ST (P = 0.030, d = 0.81) was found in PWHA (Figure 4). 
The consequence of these results is increased co‐activation be‐
tween antagonistic and synergistic muscles.
3.3 | Cluster analysis of HJHS of knee and ankle and 
Walk‐DMC index
The k‐means	 cluster	 analysis	 for	 the	 HJHS	 score	 resulted	 in	 two	
clusters. The silhouette value was 0.74 ± 0.12 for cluster 1 and 
0.68 ± 0.06 points for cluster 2 (Figure 5A). Cluster 1 is character‐
ized	by	a	low	HJHS	score	in	the	knee	and	cluster	2	by	a	high	HJHS	
value in the knee (Figure 5B). The pain level and velocity during gait 
were similar between clusters (P > 0.05) (Table 3).
When compared at the similar velocity, one‐way ANOVA re‐
vealed a significant group effect on Walk‐DMC (P = 0.019, 2
p
 = 0.29). 
Post hoc analysis indicated a significant difference only between 
cluster 2 and the CG (P = 0.016, d = 1.65) (Figure 5C). No differences 
between clusters (P = 0.245, d = 0.83) and between cluster 1 and the 
CG (P = 0.921, d = 0.41) were observed.
4  | DISCUSSION
The main results of this study are as follows: (a) that on average the 
complexity of neuromuscular control (ie the extent of muscle co‐ac‐
tivation) during gait in PWHA was different from healthy controls; 
and (b) that the complexity of neuromuscular control (Walk‐DMC) 
F I G U R E  2   The total variance accounted for (tVAF) by one to four muscle synergies. A comparison between the control group (CG) during 
walking at the preferred (CG‐pref) and at the slow (CG‐slow) velocity and people with haemophilic arthropathy (PWHA) during walking 
at preferred velocity is shown. *P < 0.05 significant difference between CG and PWHA. Data are expressed as mean and 95% confidence 
intervals (n = 13 for both groups)
F I G U R E  3   Dynamic Motor Control Index during Walking 
(Walk‐DMC). A comparison between the control group during 
preferred (CG‐pref) and slow walking velocity (CG‐slow) and people 
with haemophilic arthropathy (PWHA) during preferred walking 
velocity. Blue horizontal dashed line indicates the normal value of 
Walk‐DMC. Black horizontal dashed line indicates the 80 points of 
Walk‐DMC, which is equal to two standard deviations (SD) from 
the normal value. *P < 0.05 significant difference between groups. 
The open circles indicate the individual data. Data are expressed as 
mean and 95% confidence intervals (n = 13 for both groups)
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was	not	correlated	with	ankle	and	knee	joint	health	status	(HJHS).	
To the authors’ current knowledge, this study is the first to suggest 
an increased co‐activation between synergistic and antagonistic 
muscles during gait in PWHA. This is clinically relevant, because a 
greater co‐activation between antagonistic muscles could result in 
more intra‐articular loading, resulting in greater progression of the 
osteoarthritis.31
The number of muscle synergies for tVAF > 90% in PHWA 
was not different than that in the CG. This is in agreement with 
previous reports on effects of musculoskeletal diseases.17‐19 In 
contrast, several studies have reported a lower number of muscle 
synergies in neurological diseases.12,13 As the number of synergies 
is not a very distinctive measure, we also assessed other metrics 
of the complexity of neuromuscular control. We found significant 
F I G U R E  4   Comparisons of muscle contributions of each synergy during gait at the same velocity (ie 1 m/s). A, Comparisons of muscle 
contributions. Dashed blue line indicates the dominant muscle groups for each synergy. B, Schematic representation of the contribution of 
different muscles during gait. Dashed line and blue zone indicate the dominant muscle groups during each of the four phases. BF, Biceps 
Femoris; GMAX, Gluteus Maximus; GMED, Gluteus Medius; LG, Lateral Gastrocnemius; MG, Medial Gastrocnemius; RF, Rectus Femoris; 
SOL, Soleus; ST, Semitendinosus; TA, Tibialis Anterior; VL, Vastus Lateralis; VM, Medialis. Muscle weightings for each synergy (W). Slow 
walking velocity for the control group (CG‐slow) and people with haemophilic arthropathy (PWHA) *P<0.05 significant difference between 
groups. Data are expressed as mean and 95% confidence intervals (n = 13 for both groups)




during Walking (Walk‐DMC) at the same velocity (ie 1 m/s) between the control group during slow walking velocity (CG‐slow, n=13), cluster 
1 (n = 6) and cluster 2 (n = 7). Black horizontal dashed line indicates the 80 points of Walk‐DMC, what is equal to two standard deviations 
(SD) from the normal value. *P < 0.05 significant difference between groups. Data are expressed as the mean and 95% confidence intervals. 
The circle indicates the individuals
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differences between PWHA and CG for tVAF1 and Walk‐DMC. 
For tVAF1, the mean difference between PWHA and CG was more 
than 7%. This difference between groups is higher than inter‐day 
measurement error of the tVAF1 reported for patients with cere‐
bral palsy (ie 5%).21 At the individual level, there was quite some 
overlap of Walk‐DMC values between the two clusters for PWHA 
and CG. This suggests that some PWHA have normal neuromuscu‐
lar control of gait.
The higher tVAF1 and lower Walk‐DMC in PHWA can be ex‐
plained by more co‐activation of synergists and antagonists (see 
Figure 1). This is supported the increased co‐activation of knee flex‐
ors and extensors during acceptance and push‐off synergies (see 
Figure 4). Both results have been interpreted as indications of more 
simplified control by the CNS during gait.13,15
The z‐score normalization of tVAF1 (ie Walk‐DMC) has some ad‐
vantages compared to the tVAF1. It is affected less by the different 
methods of EMG processing and it can be better compared across 
studies.20
The observed changes in neuromuscular control may be ex‐
plained by different mechanisms. (a) Adaptations of the CNS to pain. 
Considering the temporal distinction between acute and chronic 
pain, different sources of pain, such intra‐articular bleeding, inflam‐
mation of synovium and joint degeneration, as well alteration in pain 
perception in PWHA (eg altered central pain mechanisms)32 may 
change the kinematics and kinetics of gait.33 However, the pain lev‐
els during walking in the PWHA of the present study were rather low 
(see Table 1 and 2). Therefore, we do not expect pain to play an im‐
portant role in our results. (b) The reduced range of ankle and knee 
joint motion. The chronic limitation of range of motion and disuse of 
the affected limb in PWHA may affect the mechanical properties of 
muscle and tendon .2 Previous studies reported moderate‐to‐high 
correlations between muscle weakness and tVAF1 in patients with 
cerebral palsy and Duchenne muscular dystrophy .34 In the present 
study, we did not find a significant correlation between the total 
HJHS	 score	 and	Walk‐DMC.	However,	 this	may	 be	 related	 to	 the	
limitations	of	 the	HJHS	score.	The	HJHS	 involves	a	qualitative	as‐
sessment with a small resolution (ie few levels), manual testing of 
force and testing range of motion during passive conditions only. 
We propose to include quantitative assessments of muscle strength 
and measurements of joint range of motion during gait in future 
studies. On the other hand, the subgroup of PWHA with an impair‐
ment of both knee and ankle joints showed a decrease in complex‐
ity of neuromuscular control (Walk‐DMC) during gait compared to 
the subgroup with limitations in only the ankle joint. This indicates 
that neuromuscular control of gait is affected more in multi‐joint 
impairment. (c) Disrupted proprioception. In PWHA, alterations in 
proprioceptive performance have been reported (ie angle‐repro‐
duction test).2 (d) Impaired postural control. It has also been shown 
that static balance control is affected in PWHA.35,36 The enhanced 
co‐activation between flexors and extensors during gait, increasing 
joint stiffness, could be related to the reduced proprioception and 
impaired postural control.37,38
In the clinical context, the tVAF1 and Walk‐DMC may be of addi‐
tive value to assess the quality of neuromuscular control. Different 
approaches have been reported to enhance muscle function and 
joint range of motion, and reduce pain in PWHA.39 However, in 
PWHA little is known about the impact of physical therapy on neu‐
romuscular control. The selection of the best exercise protocol to 
reduce the extent of co‐activation between joint flexor and extensor 
muscles could be relevant to prevent joint deterioration.31,33,37 This 
Clinical variables Cluster 1 (n = 6) Cluster 2 (n = 7) P‐value
Evaluated limb
HJHS	ankle	(points) 6.8 ± 3.8 7.3 ± 2.9 0.814
HJHS	knee	(points) 1.0 ± 1.2 10 ± 1.9 <0.001**
Sum	HJHS	knee	and	ankle	
(points)
7.8 ± 3.7 17.3 ± 3.7 <0.001**
Contralateral limb
HJHS	ankle	(points) 3.7 ± 4.5 6.6 ± 5.0 0.300
HJHS	knee	(points) 1.2 ± 1.3 6.1 ± 6.0 0.077
Sum	HJHS	knee	and	ankle	
(points)
4.8 ± 4.2 12.7 ± 10.5 0.113
Pain and walking
Pain during walking (VAS 
0‐10)
0 (0.5) 0 (0.6) 0.334
Preferred velocity in 30 m 
(m/s)




Parametric distribution: Mean ± SD. Nonparametric distribution: Median [Range].
HJHS,	Hemophilia	Joint	Health	Score;	VAS,	Visual	Analogue	Scale.
**P‐value <0.001 for comparison between clusters. 
TA B L E  3   Clinical characteristic 
between clusters in PWHA
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may help to improve solutions for rehabilitation after conservative 
treatment and orthopaedic surgery.39,40
A limitation of this study is that joint kinematics and kinetics 
were not assessed. Therefore, it is unclear if the gait movement pat‐
tern and mechanics were different in PWHA, and if this was related 
to the changes in neuromuscular control. In addition, a thorough 
analysis of the relationship between joint structure, muscle dysfunc‐
tion and neuromuscular control is warranted, by adding radiological 
exams such as computed tomography, magnetic resonance imaging 
and sonography.
5  | CONCLUSION
The complexity of neuromuscular control during gait was reduced 
in PWHA by means of increased co‐activation between synergistic 
and antagonistic muscles. Our results indicate that neuromuscular 
control is affected more in PWHA with multi‐joint damage com‐
pared to single joint damage. The tVAF1 and Walk‐DMC may be use‐
ful measures to assess changes in neuromuscular control in PWHA 
before and after rehabilitation therapies and or orthopaedic surgical 
interventions.
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